Intraosseous vs. Intravenous Vancomycin Prophylaxis for Diabetic Foot Amputations: A Randomized Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-03

Study Completion Date

2026-06-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

he purpose of this study is to compare the effects of two different ways of giving the antibiotic vancomycin to prevent infections in patients undergoing amputation due to diabetic foot infection. Patients with diabetes often have poor blood circulation in their legs, which may prevent standard intravenous (IV) antibiotics from reaching the surgical site in high enough concentrations.

This study compares:

Intraosseous (IO) Administration: Giving the antibiotic directly into the bone at the amputation site during surgery.

Intravenous (IV) Administration: Giving the antibiotic through a standard vein infusion before surgery.

The researchers want to find out if the intraosseous method:

Reduces the rate of surgical site infections compared to the standard IV method.

Causes fewer changes in kidney function (measured by serum creatinine levels). Decreases the need for additional surgeries (reoperations) within 90 days. Patients will be randomly assigned to either the IO or IV group and will be followed for up to 90 days to evaluate their recovery and clinical outcomes

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Optimal Antibiotics for Operated Diabetic Foot Infections

NCT04081792

Diabetic Foot Infection Surgical Wound Antibiotic Side Effect +1 more

COMPLETED NA

Less Infections for the Diabetic Foot

NCT03615807

Diabetic Foot

COMPLETED NA

Evaluating the Healing of Diabetic Foot Ulcers With Compounded Anti-Infective Irrigation Therapy

NCT05076955

Diabetic Foot Ulcer

UNKNOWN EARLY_PHASE1

Analyzing Anesthetic Techniques in Diabetic Foot Amputation

NCT06552910

Diabetic Foot Amputation, Surgical

RECRUITING

The Therapeutical Role of Continuous Intra-femoral Artery Infusion of Urokinase on Diabetic Foot Ulcers

NCT01108120

Diabetic Foot Ulcer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

DETAILED DESCRIPTION THE SURGICAL MANAGEMENT OF DIABETIC FOOT INFECTIONS IS OFTEN COMPLICATED BY PERIPHERAL VASCULAR DISEASE, WHICH SIGNIFICANTLY IMPAIRS THE DELIVERY OF SYSTEMIC PROPHYLACTIC ANTIBIOTICS TO THE INFECTED OR ISCHEMIC EXTREMITY. THIS PROSPECTIVE, RANDOMIZED, CONTROLLED STUDY INVESTIGATES WHETHER INTRAOSSEOUS (IO) ADMINISTRATION OF VANCOMYCIN PROVIDES A SUPERIOR CLINICAL OUTCOME BY DELIVERING HIGHER LOCAL TISSUE CONCENTRATIONS COMPARED TO TRADITIONAL INTRAVENOUS (IV) ADMINISTRATION.

STUDY RATIONALE AND HYPOTHESIS: PREVIOUS STUDIES IN TOTAL KNEE ARTHROPLASTY HAVE SHOWN THAT IO ADMINISTRATION INCREASES LOCAL ANTIBIOTIC TISSUE CONCENTRATION WHILE REDUCING SYSTEMIC LEVELS. DUE TO PERIPHERAL VASCULAR DISEASE IN DIABETIC FOOT PATIENTS, WE BELIEVE THAT SYSTEMICALLY ADMINISTERED VANCOMYCIN (IV) WILL REACH LOWER CONCENTRATIONS AT THE SURGICAL SITE. WE HYPOTHESIZE THAT INTRAOSSEOUS VANCOMYCIN WILL ACHIEVE SIGNIFICANTLY HIGHER DRUG LEVELS IN THE AMPUTATION STUMP AREA, REDUCE THE RATE OF SURGICAL SITE INFECTIONS (SSI), RESULT IN SMALLER INCREASES IN SERUM CREATININE LEVELS DUE TO LOWER SYSTEMIC EXPOSURE, AND DECREASE THE NECESSITY FOR REOPERATION (RTOR) IN PATIENTS UNDERGOING TRANSTIBIAL AMPUTATION.

METHODOLOGY AND INTERVENTIONS: PATIENTS ARE RANDOMIZED IN A 1:1 RATIO INTO TWO TREATMENT ARMS:

IO GROUP: DURING THE AMPUTATION PROCEDURE, 500 MG OF VANCOMYCIN IS ADMINISTERED VIA THE INTRAOSSEOUS ROUTE DIRECTLY AT THE AMPUTATION SITE.

IV GROUP: PATIENTS RECEIVE 500 MG OF VANCOMYCIN INTRAVENOUSLY 15-30 MINUTES PRIOR TO THE SURGICAL INCISION.

PHARMACOKINETIC EVALUATION (PRIMARY FOCUS): VANCOMYCIN CONCENTRATIONS WILL BE MEASURED FROM BOTH THE STUMP SITE (LOCAL TISSUE) AND SYSTEMIC CIRCULATION (PERIPHERAL BLOOD) TO COMPARE THE DISTRIBUTION AND CONCENTRATION GRADIENTS OF THE DRUG BETWEEN THE TWO ADMINISTRATION ROUTES. SAMPLES WILL BE COLLECTED INTRAOPERATIVELY TO DETERMINE IF THE IO ROUTE BYPASSES VASCULAR INSUFFICIENCY.

FOLLOW-UP AND OUTCOME EVALUATION: PATIENTS WILL BE FOLLOWED POSTOPERATIVELY ON DAYS 1,2,3,7 AND 30 FOR CLINICAL OUTCOMES ACCORDING TO CDC CRITERIA. SECONDARY OUTCOMES, INCLUDING SERUM CREATININE LEVELS TO MONITOR RENAL SAFETY AND REOPERATION RATES (REVISION AMPUTATION, DEBRIDEMENT), WILL BE TRACKED FOR UP TO 90 DAYS. MULTIVARIATE LOGISTIC REGRESSION WILL BE USED TO ADJUST FOR CONFOUNDING FACTORS SUCH AS AGE, GENDER, AND HBA1C LEVELS.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Foot Disease Diabetic Foot Infection Diabetic Amputation Foot Wound

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

PROSPECTIVE, RANDOMIZED, PARALLEL-ASSIGNMENT, CONTROLLED CLINICAL TRIAL. PATIENTS ARE RANDOMLY ASSIGNED TO EITHER THE INTRAOSSEOUS (IO) VANCOMYCIN GROUP OR THE INTRAVENOUS (IV) VANCOMYCIN GROUP IN A 1:1 RATIO.

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intraosseous Vancomycin

500 mg Vancomycin hydrochloride dissolved in of %0.9 NaCl, administered directly into the intramedullary space.

Group Type EXPERIMENTAL

Intraosseous Vancomycin

Intervention Type DRUG

A single dose of 500 mg Vancomycin is administered into the bone marrow (intraosseous route) to achieve high local tissue concentrations at the surgical site.

Intravenous Vancomycin

500 mg Vancomycin hydrochloride administered via peripheral intravenous infusion

Group Type ACTIVE_COMPARATOR

Intravenous Vancomycin

Intervention Type DRUG

A single dose of 500 mg Vancomycin is administered via systemic intravenous infusion for standard prophylactic care.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intraosseous Vancomycin

A single dose of 500 mg Vancomycin is administered into the bone marrow (intraosseous route) to achieve high local tissue concentrations at the surgical site.

Intervention Type DRUG

Intravenous Vancomycin

A single dose of 500 mg Vancomycin is administered via systemic intravenous infusion for standard prophylactic care.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

PATIENTS AGED 18 YEARS AND OLDER. DIAGNOSED WITH TYPE 1 OR TYPE 2 DIABETES MELLITUS. SCHEDULED FOR TRANSTIBIAL (BELOW-KNEE) AMPUTATION DUE TO DIABETIC FOOT INFECTION.

WILLING AND ABLE TO PROVIDE WRITTEN INFORMED CONSENT.

Exclusion Criteria

KNOWN ALLERGY OR HYPERSENSITIVITY TO VANCOMYCIN.

PRE-EXISTING RENAL INSUFFICIENCY (BASELINE SERUM CREATININE \> 2.0 MG/DL OR GFR \< 30 ML/MIN).

PREGNANCY OR BREASTFEEDING.

PREVIOUS SURGICAL INTERVENTION OR AMPUTATION ON THE SAME EXTREMITY.

BODY MASS INDEX (BMI) OVER 35.

CONTRAINDICATION TO STANDARD PROPHYLACTIC ANTIBIOTICS.

INABILITY TO LOCALIZE THE TIBIAL TUBERCLE FOR INTRAOSSEOUS INFUSION.

IMMUNOCOMPROMISED STATUS (HIV, HEPATITIS C, END-STAGE RENAL DISEASE, DIALYSIS, ACTIVE CHEMOTHERAPY OR RADIOTHERAPY).

USE OF IMMUNOSUPPRESSIVE DRUGS WITHIN THE LAST 6 MONTHS.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No